Rinat Ariely - Publications, H-index & Citations

Rinat Ariely

teva pharmaceutical industries

12H指数

72论文数

1.6K被引数

收录论文 18

发表时间

6 Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice

CHEST

IF8.6

2021-05-01

PREAI

Wechsler, Michael E.; Peters, Stephen P.; Hill, Tanisha D.; Ariely, Rinat; DePietro, Michael R.; Driessen, Maurice T.; Terasawa, Emi L.; Thomason, Darren R.; Panettieri, Reynold A., Jr.

Clinical and Economic Outcomes in Patients with Persistent Asthma Who Attain Healthcare Effectiveness and Data Information Set Measures

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE

IF6.6

2020-11-01

OAAI

Mosnaim, Giselle; Huang, Huan; Ariely, Rinat; DePietro, Michael; Jiang, Miao; Ramakrishnan, Karthik; Batista, Alberto E.; Lang, Kathy; Near, Aimee M.

Asthma control is associated with economic outcomes, work productivity and health-related quality of life in patients with asthma

BMJ OPEN RESPIRATORY RESEARCH

IF3.4

2020-03-18

OAAI

Lee, Lulu K.; Ramakrishnan, Karthik; Safioti, Guilherme; Ariely, Rinat; Schatz, Michael

Economic Outcomes Associated with Attainment of Healthcare Effectiveness and Data Information Set (HEDIS) Measures in Patients with Persistent Asthma (PA): Stratification by Attainment of Medication Management (MM) and/or Asthma Medication Ratio (AMR)

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IF11.2

2019-02-01

OAAI

Huang, Huan; Near, Aimee; Ariely, Rinat; DePietro, Michael; Jiang, Miao; Batista, Alberto; Ramakrishnan, Karthik; Mosnaim, Giselle

HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH PERSISTENT ASTHMA BY ATTAINMENT OF HEALTHCARE EFFECTIVENESS AND DATA INFORMATION SET (HEDIS) MEASURES

VALUE IN HEALTH

IF6

2018-05-01

OAAI

Mosnaim, G.; Ariely, R.; Depietro, M.; Near, A.; Huang, H.; Batista, A.; Lang, K.

Real-world Study Characterizing Patients Prior to Receiving Albuterol Multidose Dry Powder Inhaler or Short-acting β2-Agonist Via Pressurized Metered-Dose Inhalers for Asthma and COPD in the United States

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IF11.2

2018-02-01

OAAI

Bensch, Gregory; Parker, Emily D.; Ariely, Rinat; Stoyanov, Stanislav; Ramakrishnan, Karthik

The economic impact of uncontrolled asthma among treated, adherent patients with persistent asthma

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IF11.2

2018-02-01

OAAI

Lee, Lulu K.; Lugogo, Njira L.; Carpinella, Colleen; Ariely, Rinat; Gabriel, Susan; Mosnaim, Giselle

Digital Technology Interventions and Their Outcomes in Moderate-to-Severe Asthmatic Patients: A Targeted Literature Review

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IF11.2

2018-02-01

OAAI

Parcher, Benjamin; Gabriel, Susan; Ruiz, Kimberly; Ariely, Rinat; Mosnaim, Giselle

The impact of uncontrolled asthma on quality of life among treated, adherent patients with persistent asthma

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IF11.2

2018-02-01

OAAI

Mosnaim, Giselle; Lee, Lulu K.; Carpinella, Colleen; Ariely, Rinat; Gabriel, Susan; Lugogo, Njira L.

Real-world health care utilization in asthma patients using albuterol sulfate inhalation aerosol (ProAir® HFA) with and without integrated dose counters

JOURNAL OF ASTHMA AND ALLERGY

IF3

2017-05-01

OAAI

Kerwin, Edward M.; Ferro, Thomas J.; Ariely, Rinat; Irwin, Debra E.; Parikh, Ruchir

COMORBIDITIES OF SWEDISH PATIENTS DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND/OR ASTHMA

THORAX

IF7.7

2016-11-15

OAAI

Johansson, G.; Jansen, C.; Van der Tol, M.; Ariely, R.; Bergman, G.; Uhde, M.; Sobocki, P.; Benhaddi, H.

Real-life effectiveness of budesonide/formoterol for the management of asthma and COPD

EUROPEAN RESPIRATORY JOURNAL

IF21

2016-11-08

PREAI

Benhaddi, Hicham; Van der Tol, Marianka; Price, David; Khalikulov, Bakhtiyor; Ariely, Rinat

REAL-LIFE PERSISTENCE OF BUDESONIDE/FORMOTEROL SPIROMAX FOR THE MANAGEMENT OF ASTHMA AND COPD IN THE UK

VALUE IN HEALTH

IF6

2016-11-01

OAAI

Benhaddi, H.; Van der Tol, M.; Price, D.; Batsiou, M.; Ariely, R.

A MODEL FRAMEWORK EVALUATING FACTORS AFFECTING THE VALUE OF TREATMENT ONE YEAR FOLLOWING AN ACUTE CORONARY SYNDROME EVENT

VALUE IN HEALTH

IF6

2013-05-01

OAAI

Ariely, R.; Klein, R.; Gahn, J. C.; Tham, W. K.; Cohen, D.; Bell, C.; Tynan, A.

MEDICAL RESOURCE UTILIZATION AND COSTS FOLLOWING HOSPITALIZATION OF PATIENTS WITH CHRONIC HEART FAILURE IN THE UNITED STATES

VALUE IN HEALTH

IF6

2011-05-01

OAAI

Korves, C.; Eldar-Lissai, A.; Rodermund, D.; Swallow, E.; Cummings, A. K.; Ariely, R.; Duh, M. S.

DOES GENERIC ALENDRONATE REALLY SAVE MONEY IN THE TREATMENT OF OSTEOPOROSIS GIVEN SUB-OPTIMAL REAL LIFE COMPLIANCE? AN EXAMPLE FROM THE DANISH SETTING

VALUE IN HEALTH

IF6

2009-10-01

OAAI

Ariely, R.; Tambour, M.; Olson, M.

Outcomes following a hip fracture and length of hospitalization

BONE

IF3.6

2009-06-01

PREAI

de Vries, F.; Gallagher, A.; Ariely, R.; van Staa, T.

Excess mortality following hip fracture: a systematic epidemiological review 髋部骨折后的超额死亡率: 系统流行病学综述

OSTEOPOROSIS INTERNATIONAL

IF5.4

2009-05-07

832

PREAI

Abrahamsen, B.; van Staa, T.; Ariely, R.; Olson, M.; Cooper, C.

研究方向